Abstract: A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.

Abstract: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.

Abstract: A vehicle seat belt apparatus includes: a webbing; a lap anchor to which one end portion of the webbing is fixed and that is pivotable in a vehicle longitudinal direction; and a position retaining member that allows the webbing to be slidably inserted therethrough, and that is rigid in the vehicle longitudinal direction and is flexible and elastic in a vehicle transverse direction. In a seat belt retracted state, the position retaining member extends obliquely forward and upward from a lower end portion, and an upper end portion is located ahead of a side support of a seat back and above a seat shield.

Abstract: Disclosed is a stripping agent that can easily strip a photoresist residue and the like at a low temperature in a short time and, at the same time, does not corrode a wiring material at all and has no need to use an organic solvent such as alcohol as a rinsing liquid. The stripping agent disclosed herein comprises 5 to 50% by mass of a specific amine, 30 to 65% by mass of a specific acid amide, 0.1 to 15% by mass of a saccharide or a sugar alcohol, and 1 to 64.5% by mass of water.

Abstract: Disclosed is a stripping agent that can easily strip a photoresist residue and the like at a low temperature in a short time and, at the same time, does not corrode a wiring material at all and has no need to use an organic solvent such as alcohol as a rinsing liquid. The stripping agent disclosed herein comprises 5 to 50% by mass of a specific amine, 30 to 65% by mass of a specific acid amide, 0.1 to 15% by mass of a saccharide or a sugar alcohol, and 1 to 64.5% by mass of water.

Abstract: The present invention developed a novel antitumor agent for renal cell carcinoma that cannot be fully treated by the existing therapies. The present invention provides an antitumor agent comprising a combination drug of tegafur/gimeracil/oteracil potassium that ensures an excellent therapeutic effect in renal cell carcinoma patients that is superior to that of the existing therapies, by way of selecting the patients based on thymidylate synthase.

Abstract: A vehicle seat belt apparatus includes: a webbing; a lap anchor to which one end portion of the webbing is fixed and that is pivotable in a vehicle longitudinal direction; and a position retaining member that allows the webbing to be slidably inserted therethrough, and that is rigid in the vehicle longitudinal direction and is flexible and elastic in a vehicle transverse direction. In a seat belt retracted state, the position retaining member extends obliquely forward and upward from a lower end portion, and an upper end portion is located ahead of a side support of a seat back and above a seat shield.

Abstract: The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.

Abstract: A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.

Abstract: The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator.

Abstract: A tumor marker comprising diacetylspermine, and a method of evaluating the state of a tumor, comprising reacting an antibody to diacetylspermine with a biological sample to thereby detect diacetylspermine and evaluating the state of the tumor using the obtained detection results as an indicator.